National Pension Service Has $121,000 Stock Position in Moderna, Inc. $MRNA

National Pension Service boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 262.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,387 shares of the company’s stock after purchasing an additional 3,175 shares during the period. National Pension Service’s holdings in Moderna were worth $121,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. S Bank Fund Management Ltd acquired a new stake in shares of Moderna during the first quarter worth approximately $25,000. Atlantic Union Bankshares Corp bought a new stake in Moderna during the 2nd quarter worth approximately $26,000. TD Private Client Wealth LLC grew its position in Moderna by 348.8% during the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after acquiring an additional 743 shares during the last quarter. Whittier Trust Co. acquired a new stake in Moderna during the 2nd quarter valued at $28,000. Finally, SVB Wealth LLC bought a new position in Moderna in the 1st quarter valued at $28,000. 75.33% of the stock is owned by institutional investors.

Moderna Trading Down 0.8%

Shares of NASDAQ MRNA opened at $24.77 on Friday. Moderna, Inc. has a 1 year low of $23.04 and a 1 year high of $48.92. The firm’s 50-day moving average is $25.92 and its 200-day moving average is $27.07. The firm has a market capitalization of $9.68 billion, a PE ratio of -3.07 and a beta of 2.02.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. During the same period in the prior year, the business posted $0.03 earnings per share. Moderna’s revenue was down 45.4% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on MRNA. Barclays decreased their target price on Moderna from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Evercore ISI set a $32.00 price objective on shares of Moderna in a research report on Friday, August 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Bank of America decreased their price target on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a research note on Monday, November 10th. Finally, UBS Group dropped their price objective on shares of Moderna from $70.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $35.85.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.